Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSU-2131 Vaccine in Healthy Volunteers and Patients Awaiting Solid Organ Transplantation
NCT06741072Phase 1Recruiting
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Jun 2026
- Primary completion
- Jul 2027
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Epstein-Barr virus infection comparing Group I (OSU-2131, QS-21) with Group II (placebo) (2 arms). Primary endpoints: Incidence of treatment-emergent adverse events at 28 weeks, Changes in laboratory parameters and vital signs at 56 weeks and 2 more. Started Jun 2026; status: recruiting.
02
Drugs
OSU-2131
03
Conditions
Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT06741072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06741072.